2023-2029 Global Multiparametric In-vitro Cardiotoxicity Testing Industry Research & Trends Analysis Report
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
According to the latest research analysis,the global market for Multiparametric In-vitro Cardiotoxicity Testing should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Multiparametric In-vitro Cardiotoxicity Testing market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Multiparametric In-vitro Cardiotoxicity Testing market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type of assay, Calcium Transient Assay segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Contract Research Organizations (CROs) has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Multiparametric In-vitro Cardiotoxicity Testing include Creative Bioarray, Agilent Technologies, Inc., Hemogenix Inc., Merck KGaA, Molecular Devices, LLC., Miltenyi Biotec, FUJIFILM Cellular Dynamics, Enzo Life Sciences, Inc. and Axol Bioscience Ltd., etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive study of the global market for Multiparametric In-vitro Cardiotoxicity Testing.
Data-Driven Insights: Highlights from Our Report
(1) Global Multiparametric In-vitro Cardiotoxicity Testing market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Multiparametric In-vitro Cardiotoxicity Testing market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Multiparametric In-vitro Cardiotoxicity Testing market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Multiparametric In-vitro Cardiotoxicity Testing segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Multiparametric In-vitro Cardiotoxicity Testing segment by type and by application and regional segment by type and by application.
(6) Multiparametric In-vitro Cardiotoxicity Testing industry supply chain, upstream, midstream and downstream analysis.
Breaking Down Market Segments by Region: A Deep Dive Analysis
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by type of assay, covers
Calcium Transient Assay
Cardiac Marker Detection
hERG Assay
Multi-ion Channel Assay
Others
Market Segmentation by Application: Dividing Key Markets and Identifying Opportunities
Contract Research Organizations (CROs)
Pharmaceutical and Biotech Companies
Others
Understanding Market Segments by Key Players: Insights and Opportunities
Creative Bioarray
Agilent Technologies, Inc.
Hemogenix Inc.
Merck KGaA
Molecular Devices, LLC.
Miltenyi Biotec
FUJIFILM Cellular Dynamics
Enzo Life Sciences, Inc.
Axol Bioscience Ltd.
emka TECHNOLOGIES
Eurofins Discovery
Stemina Biomarker Discovery, Inc.
Evotec
1 Market Overview
1.1 Product Overview and Scope of Multiparametric In-vitro Cardiotoxicity Testing
1.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast
1.3 China Multiparametric In-vitro Cardiotoxicity Testing Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Multiparametric In-vitro Cardiotoxicity Testing Share in Global Market, 2018-2029
1.4.2 Multiparametric In-vitro Cardiotoxicity Testing Market Size: China VS Global, 2018-2029
1.5 Multiparametric In-vitro Cardiotoxicity Testing Market Dynamics
1.5.1 Multiparametric In-vitro Cardiotoxicity Testing Market Drivers
1.5.2 Multiparametric In-vitro Cardiotoxicity Testing Market Restraints
1.5.3 Multiparametric In-vitro Cardiotoxicity Testing Industry Trends
1.5.4 Multiparametric In-vitro Cardiotoxicity Testing Industry Policy
2 Global Competitive Situation by Company
2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Revenue by Company (2018-2023)
2.2 Global Multiparametric In-vitro Cardiotoxicity Testing Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Multiparametric In-vitro Cardiotoxicity Testing Concentration Ratio
2.4 Global Multiparametric In-vitro Cardiotoxicity Testing Mergers & Acquisitions, Expansion Plans
2.5 Global Multiparametric In-vitro Cardiotoxicity Testing Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Multiparametric In-vitro Cardiotoxicity Testing Revenue by Company (2018-2023)
3.2 China Multiparametric In-vitro Cardiotoxicity Testing Multiparametric In-vitro Cardiotoxicity Testing Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Multiparametric In-vitro Cardiotoxicity Testing, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Multiparametric In-vitro Cardiotoxicity Testing Industry Chain
4.2 Multiparametric In-vitro Cardiotoxicity Testing Upstream Analysis
4.3 Multiparametric In-vitro Cardiotoxicity Testing Midstream Analysis
4.4 Multiparametric In-vitro Cardiotoxicity Testing Downstream Analysis
5 Sights by Type of Assay
5.1 Multiparametric In-vitro Cardiotoxicity Testing Classification
5.1.1 Calcium Transient Assay
5.1.2 Cardiac Marker Detection
5.1.3 hERG Assay
5.1.4 Multi-ion Channel Assay
5.1.5 Others
5.2 By Type of Assay, Global Multiparametric In-vitro Cardiotoxicity Testing Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Type of Assay, Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2018-2029
6 Sights by Application
6.1 Multiparametric In-vitro Cardiotoxicity Testing Segment by Application
6.1.1 Contract Research Organizations (CROs)
6.1.2 Pharmaceutical and Biotech Companies
6.1.3 Others
6.2 By Application, Global Multiparametric In-vitro Cardiotoxicity Testing Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
7.3 North America
7.3.1 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Multiparametric In-vitro Cardiotoxicity Testing Market Size Market Share
7.4 Europe
7.4.1 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size Market Share
7.6 South America
7.6.1 South America Multiparametric In-vitro Cardiotoxicity Testing Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Multiparametric In-vitro Cardiotoxicity Testing Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Multiparametric In-vitro Cardiotoxicity Testing Market Size & CAGR，2018 VS 2022 VS 2029
8.2 By Country, Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.3.2 By Company, U.S. Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.3.3 By Type of Assay, U.S. Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.3.4 By Application, U.S. Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.4.2 By Company, Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.4.3 By Type of Assay, Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.4.4 By Application, Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.5.2 By Company, China Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.5.3 By Type of Assay, China Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.5.4 By Application, China Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.6.2 By Company, Japan Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.6.3 By Type of Assay, Japan Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.6.4 By Application, Japan Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.7.2 By Company, South Korea Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.7.3 By Type of Assay, South Korea Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.7.4 By Application, South Korea Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.8.3 By Type of Assay, Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.8.4 By Application, Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.9.2 By Company, India Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.9.3 By Type of Assay, India Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.9.4 By Application, India Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2018-2023
8.10.3 By Type of Assay, Middle East & Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
8.10.4 By Application, Middle East & Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 Creative Bioarray
9.1.1 Creative Bioarray Company Information, Head Office, Market Area and Industry Position
9.1.2 Creative Bioarray Company Profile and Main Business
9.1.3 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.1.4 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.1.5 Creative Bioarray Recent Developments
9.2 Agilent Technologies, Inc.
9.2.1 Agilent Technologies, Inc. Company Information, Head Office, Market Area and Industry Position
9.2.2 Agilent Technologies, Inc. Company Profile and Main Business
9.2.3 Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.2.4 Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.2.5 Agilent Technologies, Inc. Recent Developments
9.3 Hemogenix Inc.
9.3.1 Hemogenix Inc. Company Information, Head Office, Market Area and Industry Position
9.3.2 Hemogenix Inc. Company Profile and Main Business
9.3.3 Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.3.4 Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.3.5 Hemogenix Inc. Recent Developments
9.4 Merck KGaA
9.4.1 Merck KGaA Company Information, Head Office, Market Area and Industry Position
9.4.2 Merck KGaA Company Profile and Main Business
9.4.3 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.4.4 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.4.5 Merck KGaA Recent Developments
9.5 Molecular Devices, LLC.
9.5.1 Molecular Devices, LLC. Company Information, Head Office, Market Area and Industry Position
9.5.2 Molecular Devices, LLC. Company Profile and Main Business
9.5.3 Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.5.4 Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.5.5 Molecular Devices, LLC. Recent Developments
9.6 Miltenyi Biotec
9.6.1 Miltenyi Biotec Company Information, Head Office, Market Area and Industry Position
9.6.2 Miltenyi Biotec Company Profile and Main Business
9.6.3 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.6.4 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.6.5 Miltenyi Biotec Recent Developments
9.7 FUJIFILM Cellular Dynamics
9.7.1 FUJIFILM Cellular Dynamics Company Information, Head Office, Market Area and Industry Position
9.7.2 FUJIFILM Cellular Dynamics Company Profile and Main Business
9.7.3 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.7.4 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.7.5 FUJIFILM Cellular Dynamics Recent Developments
9.8 Enzo Life Sciences, Inc.
9.8.1 Enzo Life Sciences, Inc. Company Information, Head Office, Market Area and Industry Position
9.8.2 Enzo Life Sciences, Inc. Company Profile and Main Business
9.8.3 Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.8.4 Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.8.5 Enzo Life Sciences, Inc. Recent Developments
9.9 Axol Bioscience Ltd.
9.9.1 Axol Bioscience Ltd. Company Information, Head Office, Market Area and Industry Position
9.9.2 Axol Bioscience Ltd. Company Profile and Main Business
9.9.3 Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.9.4 Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.9.5 Axol Bioscience Ltd. Recent Developments
9.10 emka TECHNOLOGIES
9.10.1 emka TECHNOLOGIES Company Information, Head Office, Market Area and Industry Position
9.10.2 emka TECHNOLOGIES Company Profile and Main Business
9.10.3 emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.10.4 emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.10.5 emka TECHNOLOGIES Recent Developments
9.11 Eurofins Discovery
9.11.1 Eurofins Discovery Company Information, Head Office, Market Area and Industry Position
9.11.2 Eurofins Discovery Company Profile and Main Business
9.11.3 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.11.4 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.11.5 Eurofins Discovery Recent Developments
9.12 Stemina Biomarker Discovery, Inc.
9.12.1 Stemina Biomarker Discovery, Inc. Company Information, Head Office, Market Area and Industry Position
9.12.2 Stemina Biomarker Discovery, Inc. Company Profile and Main Business
9.12.3 Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.12.4 Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.12.5 Stemina Biomarker Discovery, Inc. Recent Developments
9.13 Evotec
9.13.1 Evotec Company Information, Head Office, Market Area and Industry Position
9.13.2 Evotec Company Profile and Main Business
9.13.3 Evotec Multiparametric In-vitro Cardiotoxicity Testing Models, Specifications and Application
9.13.4 Evotec Multiparametric In-vitro Cardiotoxicity Testing Revenue and Gross Margin, 2018-2023
9.13.5 Evotec Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Research Methodology:
Global Multiparametric In vitro Cardiotoxicity Testing Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|